Prosecution Insights
Last updated: November 04, 2026
Application No. 18/684,910

CELL MATRIX NERVE GRAFT FOR REPAIRING PERIPHERAL NERVE INJURY AND PREPARATION METHOD THEREOF

Final Rejection §103§DOUBLEPATENT
Filed
Feb 20, 2024
Priority
Aug 16, 2022 — CN 202210982152.0 +1 more
Examiner
CRAIGO, WILLIAM A
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nantong University
OA Round
2 (Final)
49%
Grant Probability
Moderate
3-4
OA Rounds
9m
Est. Remaining
87%
With Interview

Examiner Intelligence

Grants 49% of resolved cases
49%
Career Allowance Rate
368 granted / 751 resolved
-11.0% vs TC avg
Strong +38% interview lift
Without
With
+38.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
45 currently pending
Career history
809
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
40.2%
+0.2% vs TC avg
§102
12.6%
-27.4% vs TC avg
§112
24.2%
-15.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 751 resolved cases

Office Action

§103 §DOUBLEPATENT
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Status of the Claims The response and amendment filed 05/07/ is acknowledged. Claims 1-8 are pending. Claims 9-18 were canceled. Applicant’s election without traverse of Group I, claims 1-3, in the reply filed on 05/19/5026 is acknowledged. Claims 4-8 remain withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 05/19/2026. Claims 1-3 are treated on the merits in this action. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Rejections not reiterated herein have been withdrawn. Withdrawn The rejection of claims 1-3 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention has been withdrawn because of Applicant’s amendment. The rejection of claims 2-3 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention has been withdrawn because of Applicant’s amendment. Response to Arguments Applicant's arguments filed 10/13/2026 have been fully considered but they are not persuasive. Applicant’s argument that Gu does not teach recombinant human collagen because Gu only teaches non-human sources is unpersuasive. Gu, 0009 teaches the ECM including collagen (Gu, e.g., 0017) is secreted by autologous or allogeneic bone marrow mesenchymal stem cells. This directs the skilled artisan to use bone marrow mesenchymal stem cells and collagen materials of the species intended to be treated. Gu clearly states the objective of the invention is to prepare biomaterials used for transplants into the human body (Gu, e.g., 0002). The skilled artisan would have understood to use human bone marrow stem cells and human collagen to prepare an autologous or allogeneic nerve graft suitable for treating humans. There does not appear to be any patentable distinction between collagen from ECM secreted by human autologous or allogeneic bone marrow mesenchymal stem cells and recombinant human collagen. Recombinant human collagen has the same protein sequence and is bioidentical to human collagen. Applicant’s argument that Gu does not teach a scaffold having the combination of human collagen and chitosan is unpersuasive. Gu, 0009 teaches the nerve conduit (scaffold) is preferably made up of one or a combination of silk fibroin, chitosan, collagen, polylactic acid or polyglycolic acid. The skilled artisan is provided with a limited, and finite, list of equivalent materials to select from for preparing the scaffold. Collagen and chitosan are clearly named. Applicant’s argument that Liang teaches an acellular matrix derived from animal tissues is unpersuasive because Gu directs the skilled artisan to use stem cells and collagen materials of the species intended to be treated, e.g., decellularized autologous or allogeneic bone marrow mesenchymal stem cells, because these avoid immunogenicity and are beneficial to neural cell adhesion and establish an environment suitable for axonal regrowth (Gu, e.g., 0007). Applicant argues that Liang teaches that its outer tube needs to be pressed by vacuum to form a dense structure to enhance the barrier function and prevent nerve fibers from overflowing, while the present invention recites a jelly like membrane which forms a tubular structure through self-assembly without vacuum pressing. Applicant argues that the claimed nerve graft is set still at 2-6° C. for at least 24 h for self-assembly to form a tubular structure to form a tubular structure with multiple layers of acellular matrix. Applicant argues the vacuum pressing of Liang is mutually exclusive and structurally antagonistic to the claimed self-assembly and freeze-drying process and therefore the skilled artisan would have no reasonable expectation of success, motivation to combine Liang and Gu, and also means Liang teaches away from the claimed invention. These arguments are unpersuasive. The skilled artisan would have been motivated to improve Gu’s nerve conduit scaffold with a multilayer sheath to improve the barrier function to surrounding tissue and enhancing directional nerve fiber regeneration (Liang, e.g., 0007) by preventing nerve fibers from escaping (Liang, e.g., 0105). Liang teaches the sheath prepared by rolling the ECM around the scaffold to form ten layers, then the vacuum pressing is done by placing in a vacuum freeze drying to dry for 24 hours (Liang, e.g., 0119) to form the tubular structure with multiple layers of acellular matrix. The prior art sheath is made from an acellular ECM matrix and therefore qualifies as a jelly like membrane when wrapped around the scaffold. Because of this, Liang does not teach away from the claimed invention. Liang’s technique results in a multilayer acellular matrix which is prepared by a process which includes keeping the material still for 24 hours at freeze-drying conditions. The disclosed process also lyophilizes the acellular matrix like the prior art. The patentability of product by process claims is determined based on the product itself. See MPEP 2113, 1. The claimed product by process step does not appear to necessarily imply any patentably distinct structure to the multilayer acellular matrix of the claimed nerve graft. The presently claimed product by process language does not exclude a vacuum pressing step. There does not appear to be any evidence of criticality or unexpected results commensurate in scope with the claimed product by process language. The proffered results appear to be present in, or expected from, the prior art. Liang teaches the decellularized matrix retains the natural scaffold structure of the extracellular matrix after decellularization (Liang, e.g., 0003). Thus, even if vacuum pressed, the prior art extracellular matrix sheath contains the natural fiber network structure and orientation. There is no evidence vacuum pressing, as done in Liang, results in damage to the natural structure of the ECM. Gu teaches the decellularized matrix material reduces immunogenicity and is beneficial to neural cell adhesion and establishes an environment suitable for axonal regrowth (Gu, e.g., 0007). There is no risk of cross species immunogenicity since Gu teaches using autologous or allogeneic materials which are necessarily from the same species for which the nerve conduit is designed for use, e.g., humans. The prior art nerve conduit allows for directional growth of nerve fibers (Gu, e.g., 0017 and Liang, e.g., 0001 and 0007). The claimed invention does not exclude a product-by-process step of vacuum pressing. Rejections Modified to Address Applicant’s Amendment Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-3 are rejected under 35 U.S.C. 103 as being unpatentable over Gu, US 20150352255 and Liang, CN 112546303. Citations to Liang refer to the attached machine translation. Gu teaches a nerve graft comprising a nerve conduit and an ECM secreted by autologous or allogeneic cells and obtained by decellularization (Gu, e.g., 0009 and claim 9). The nerve conduit corresponds to the claimed scaffold (Gu, e.g., 0010), and the ECM secreted by cell and obtained by decellularization corresponds to the claimed acellular matrix (Gu, e.g., 0011). The ECM acellular matrix is derived from bone marrow mesenchymal stem cells (Gu, e.g., claim 10). The nerve conduit is biodegradable, e.g., based on chitosan and/or collagen (Gu, e.g., claim 11). Since Gu teaches the nerve conduit may be a combination of polymers including chitosan and collagen, it would have been obvious to one of ordinary skill in the art before the effective filing date of the presently claimed invention to configure the nerve conduit as a biodegradable scaffold comprising chitosan and collagen. Gu provides an express teaching which would have prompted the skilled artisan to configure the nerve conduit (scaffold) using the claimed polymers with a reasonable expectation of success. It would have been obvious to one of ordinary skill in the art before the effective filing date of the presently claimed invention to use human BMSCs and collagen to reduce the risk of cross species immunogenicity and to promote nerve growth for human patients. Gu teaches the ECM secreted by cell and obtained by decellularization corresponding to the claimed acellular matrix is coated on the inner and outer surfaces of the nerve conduit (Gu, e.g., 0005, 0019, 0068, 0070). However, Gu does not expressly teach the acellular matrix is wrapped around the nerve conduit scaffold to form multiple layers. Liang teaches nerve repair materials like Gu, comprising a tubular shape (conduit) comprising an inner core matrix and an outer multilayered tube (Liang, e.g., claim 1), wherein the multilayer outer tube comprises 2-12 layers of decellularized (acellular) matrix (Liang, e.g., claim 2). The layer range in claim 3 is within the range suggested by Liang. Liang teaches the multilayer configuration enables a dense structure with improved barrier function (Liang, e.g., 0004), which inhibits outgrowth of nerve fibers thereby reducing the formation of neuromas (Liang, e.g., 0001, 0031, ¶ spanning pp. 19-20). This promotes the desired directional regeneration of nerve fibers (Liang, e.g., 0001). It would have been obvious to one of ordinary skill in the art before the effective filing date of the presently claimed invention to modify a nerve graft known from Gu by configuring the outer acellular matrix as a multilayered construct by rolling the matrix material around the nerve conduit to improve the device in the same way suggested by Liang with a reasonable expectation of success. The skilled artisan would have been motivated to make this modification to promote desired directional regeneration of nerve fibers and reduce the risk of neuromas in the same way reported by Liang. The skilled artisan would have had a reasonable expectation of success since both references teach improvements for nerve grafts comprising an acellular matrix. The prior art sheath is made from an acellular ECM matrix and therefore qualifies as a jelly-like membrane when wrapped around the scaffold. Accordingly, the subject matter of claims 1-3 would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the presently claimed invention, absent evidence to the contrary. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO internet Web site contains terminal disclaimer forms which may be used. Please visit http://www.uspto.gov/forms/. The filing date of the application will determine what form should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claim(s) 1-3 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim(s) 1-14 of US 9492589 in view of Liang, CN 112546303. Although the claims at issue are not identical, they are not patentably distinct from each other because: Gu teaches a nerve graft comprising a nerve conduit and an ECM secreted by autologous or allogeneic cells and obtained by decellularization (Gu, e.g., claim 9). The nerve conduit corresponds to the claimed scaffold, and the ECM secreted by cell and obtained by decellularization corresponds to the claimed acellular matrix (Gu, e.g., claim 2). The ECM acellular matrix is derived from bone marrow mesenchymal stem cells (Gu, e.g., claim 10). The nerve conduit is biodegradable, e.g., based on chitosan and/or collagen (Gu, e.g., claim 11). Since Gu teaches the nerve conduit may be a combination of polymers including chitosan and collagen, it would have been obvious to one of ordinary skill in the art before the effective filing date of the presently claimed invention to configure the nerve conduit as a biodegradable scaffold comprising chitosan and collagen. Gu provides an express teaching which would have prompted the skilled artisan to configure the nerve conduit (scaffold) using the claimed polymers with a reasonable expectation of success. It would have been obvious to one of ordinary skill in the art before the effective filing date of the presently claimed invention to use human BMSCs and collagen to reduce the risk of cross species immunogenicity and to promote nerve growth for human patients. Gu teaches the ECM secreted by cell and obtained by decellularization, corresponding to the claimed acellular matrix, is coated on the inner and outer surfaces of the nerve conduit (Gu, e.g., claim 2). However, Gu does not expressly teach the acellular matrix is wrapped around the nerve conduit scaffold to form multiple layers. Liang teaches nerve repair materials like Gu, comprising a tubular shape (conduit) comprising an inner core matrix and an outer multilayered tube (Liang, e.g., claim 1), wherein the multilayer outer tube comprises 2-12 layers of decellularized (acellular) matrix (Liang, e.g., claim 2). The layer range in claim 3 is within the range suggested by Liang. Liang teaches the multilayer configuration enables a dense structure with improved barrier function (Liang, e.g., 0004), which inhibits outgrowth of nerve fibers thereby reducing the formation of neuromas (Liang, e.g., 0001, 0031, ¶ spanning pp. 19-20). This promotes the desired directional regeneration of nerve fibers (Liang, e.g., 0001). It would have been obvious to one of ordinary skill in the art before the effective filing date of the presently claimed invention to modify a nerve graft known from Gu by configuring the outer acellular matrix as a multilayered construct by rolling the matrix material around the nerve conduit to improve the device in the same way suggested by Liang with a reasonable expectation of success. The skilled artisan would have been motivated to make this modification to promote desired directional regeneration of nerve fibers and reduce the risk of neuromas in the same way reported by Liang. The skilled artisan would have had a reasonable expectation of success since both references teach improvements for nerve grafts comprising an acellular matrix. The prior art sheath is made from an acellular ECM matrix and therefore qualifies as a jelly-like membrane when wrapped around the scaffold. Accordingly, the subject matter of claims 1-3 would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the presently claimed invention, absent evidence to the contrary. Conclusion No claim is allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to WILLIAM A CRAIGO whose telephone number is (571)270-1347. The examiner can normally be reached on Monday - Friday, 9am - 6pm, PDT. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A WAX can be reached on 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /WILLIAM CRAIGO/Examiner, Art Unit 1615 /SUSAN T TRAN/Primary Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Feb 20, 2024
Application Filed
Jul 31, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT
Oct 13, 2026
Response Filed
Oct 29, 2026
Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758633
CARRIER FOR PROMOTING FENTON REACTION AND PREPARATION PROCESS AND USES THEREOF
2y 12m to grant Granted Oct 13, 2026
Patent 12740939
ELASTOMERIC MATRICES BASED ON PLASTICIZED PVOH COMPOSITIONS AND USES THEREOF
2y 5m to grant Granted Sep 22, 2026
Patent 12734279
BIOABSORBABLE MEDICAL MATERIAL
3y 11m to grant Granted Sep 15, 2026
Patent 12734130
PHARMACEUTICAL COMPOSITION AND METHOD FOR ENHANCING SOLUBILITY OF POORLY SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS
3y 4m to grant Granted Sep 15, 2026
Patent 12734268
EXPANDABLE HEMOSTATIC TABLETS COMPRISING OXIDIZED REGENERATED CELLULOSE
3y 10m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
49%
Grant Probability
87%
With Interview (+38.0%)
3y 6m (~9m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 751 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month